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Abstract 
Breast Cancer Associated gene 2 (BCA2) is an E3 ubiquitin ligase that is over-expressed in >50% of 
primary breast cancers, and has been shown to increase in vitro cell proliferation and invasion. The 
protein has been linked to alterations in EGFR degradation; however there is some dispute as to its 
role and influence on the biology of this receptor. Our work aimed to ascertain the role of BCA2 
in EGFR endocytosis and down-regulation and to examine its links with breast cancer outcome. 
Data generated with the online expression analysis tool KM-Plotter showed that high BCA2 levels 
are associated with poor prognosis in ovarian, gastric and breast cancer, particularly HER2 
over-expressing breast cancers. Experimentally, we demonstrate that over-expression of BCA2 
induced a reduction in total EGFR levels. BCA2 over-expressing cells stimulated with EGF 
exhibited reduced lysosomal degradation of both this ligand and its receptor. Signalling 
downstream of EGFR in BCA2 over-expressing cells was characterized by a lower magnitude but 
increased duration. Our findings support a role for BCA2 in receptor endocytosis. Consistent with 
this we show that BCA2 over-expression reduces the level of vesicle-associated Rab7, a regulator 
of late endocytosis and documented interaction partner of BCA2. Levels of transferrin receptor 
and the uptake of transferrin were unaltered by over-expression of BCA2 indicating that trafficking 
changes may be limited to late endocytic sorting events. This report offers a thorough exploration 
of BCA2 biology and suggests a context-dependent role for the protein in the endocytic regulation 
of EGFR and as a prognostic biomarker in cancer. 
Key words: BCA2 
Introduction 
Receptor tyrosine kinases (RTKs) are essential 
for normal cell function and are often over-expressed, 
ineffectively down-regulated or mutated in cancer. 
Epidermal growth factor receptor (EGFR) and human 
epidermal growth factor receptor 2 (HER2) are 
members of the ErbB family of RTKs that are of 
particular importance in breast cancer. Although 
estimates vary, EGFR over-expression is thought to 
present in approximately 30% of breast cancers while 
HER2 positivity is detected in 25-30% of cases (1, 2). 
High levels of EGFR and HER2 are associated with 
more aggressive cancer phenotypes and poorer 
prognosis (3). When activated by ligand binding and 
dimerization, RTKs are internalized and 
pro-oncogenic intracellular signalling is initiated, 
primarily via the MAPK and PI3K/Akt pathways. 
The aberrant gene expression induced by enhanced 
expression/activation of EGFR or HER2 promotes 
cancer cell proliferation, survival, migration, and 
angiogenesis (4).  
Endocytosis is the mechanism by which cells 
internalize ligand-bound RTKs, and a critical process 
for the regulation of downstream signalling (5).  
Activated receptors are removed from the cell surface 
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in vesicles that are shuttled into the cell. These vesicles 
fuse with early endosomes via the action of Rab5, a 
member of the Rab family of small GTPases that 
collectively coordinate many stages of membrane 
trafficking. Receptors are sorted in the early 
endosome and are subsequently trafficked along 
different routes (6): fast or slow recycling to the 
plasma membrane or lysosomal degradation. 
Receptor recycling maintains receptor numbers on the 
cell surface, prolongs signalling and promotes 
receptor reactivation. Rab7 controls the degradation 
pathway and is responsible for receptor sorting in late 
endosomes and transport to lysosomes for 
degradation (7). 
Proteins regulating RTK endocytosis have also 
been implicated in cancer (8) including Rab7 (9), Rab5 
(10) and the E3 ligase C-cbl (11, 12). Rab7 has been 
shown to affect cell survival and adhesion via 
co-ordination of the later stages of endocytosis (9). 
Rab7 has additionally been shown to have a role in 
endocytosis and cancer through its interaction with 
Breast Cancer Associated gene 2 (BCA2). The 
consequence of the relationship between BCA2 and 
Rab7 has been separately said to both inhibit and 
promote EGFR degradation (13-15).  
BCA2 is a RING E3 ubiquitin ligase, a family of 
enzymes involved in the post-translational 
modification of other proteins via the addition of 
small, regulatory ubiquitin tags. In addition to BCA2, 
a number of E3 ligases have been implicated in breast 
cancer including: BRCA1; RNF11; c-Cbl and Efp (16).  
Upon first identification, BCA2 was named Rabring7 
due to its interaction with Rab7 (13). The protein is 
also known as RNF115 and ZNF364 and the name 
BCA2 derives from its association with breast cancer. 
Differential display and subtractive hybridization 
screening in normal and malignant mammary cell 
lines showed that BCA2 was significantly 
up-regulated in 56% of primary breast cancers and 
74% of estrogen receptor (ER) positive disease (17). In 
vitro data from the same study suggested an 
oncogenic role: siRNA depletion of BCA2 
significantly reduced cell growth and invasion of 
T47D (ER+) breast cancer cells while over-expression 
of BCA2 in NIH3T3 (mouse fibroblast) cells increased 
proliferation by 50%. Further functional links between 
BCA2 expression and breast cancer pathology have 
since been explored by other in vitro experiments, 
clinical expression analyses and genomic studies. The 
principal findings from these studies indicate that 
BCA2: 1) is transcriptionally regulated by the ER, 2) 
can modulate the anti-breast cancer effect of the 
AMPK inhibitor metformin, 3) can promote 
proliferation of ER+ breast cancer by down-regulating 
p21, 4) has a role in regulating the DNA damage 
response, 5) is a potential susceptibility gene for 
breast cancer and 6) may serve as a potential drug 
target in anti-breast cancer therapy (18-24).  
It has been suggested, based on over-expression 
studies, that BCA2 is recruited by Rab7 to late 
endosomes and lysosomes, and that as a result EGFR 
degradation is inhibited (13). Intriguingly, BCA2 has 
also been shown to promote degradation of EGFR, as 
siRNA depletion of BCA2 in cervical cancer cells 
caused EGFR to accumulate in late endocytic 
compartments following EGF stimulation. The defects 
in EGFR degradation were attributed to a reduction in 
the number of late endosomes formed in the BCA2 
depleted cells (15).  
As the body of work on BCA2 has increased, so 
too has the apparent disparity in the literature 
surrounding the protein’s role in receptor trafficking 
and breast cancer. We therefore sought to further 
explore BCA2’s role in EGFR endocytosis, 
down-regulation and signalling. In parallel we also 
examined the relationship between BCA2 expression 
and patient survival in different breast cancer 
subtypes and in other cancers. Our results 
substantiate a role for BCA2 in EGFR endocytosis and 
signalling and link this to the sub-cellular localization 
of Rab7. BCA2 expression correlates with poorer 
prognosis in ovarian, gastric and breast cancers 
(particularly in breast cancer subtypes that 
over-express HER2).  
Materials and Methods  
Routine cell culture 
MCF-7 (ER+, HER2-), MDA-MB-231 (ER-, HER2-), 
BT474 (ER+, HER2+) and T47D (ER+, HER2-) human 
breast cancer cells were kindly donated by the Breast 
Cancer Molecular Pharmacology Group (BCMPG), 
Cardiff University. MCF-10A human breast epithelial 
cells were purchased from the ATTC’s approved UK 
supplier LGC Standards. Cervical cancer HeLa cells 
were obtained from the European Molecular Biology 
Laboratory (25).  
MCF-7, MDA-MB-231, BT474 and T47D cells 
were cultured in Roswell Park Memorial Institute 
media (RPMI) containing phenol red and 
supplemented with 10% Fetal Bovine Serum (FBS). 
MCF-10A cells were grown in Dulbecco's Modified 
Eagle Medium: Nutrient mixture F12 (DMEM/F12) 
supplemented with 5% horse serum, 20 ng/mL 
epidermal growth factor (EGF), 0.5 µg/mL 
hydrocortisone, 100 ng/mL cholera toxin and 
10 µg/mL insulin (26). HeLa cells were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% FBS.  
All cell lines were cultured at 37°C in a 5% CO2 
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humidified atmosphere. Cells were used up to a 
maximum of 28 passages and were subject to regular 
mycoplasma testing. 
Transfection  
Plasmid constructs  
The pCMV-HA plasmid containing the BCA2 
insert was a kind gift from Naoki Yamamoto at the 
AIDS Research Centre, National Institute of Infectious 
Diseases, Tokyo (27).  
pCMV6-AC-HA (PrecisionShuttle) with no 
insert DNA was used as a mock-transfection control 
in HA-BCA2 experiments.  
Fugene 6 transfection  
The following method describes volumes and 
quantities per well of a 12-well plate and quantities 
were scaled accordingly for transfections in 6- and 96- 
well plates. MCF-7 (110,000), MDA-MB-231 (75,000) 
or HeLa (67,000) cells were seeded onto coverslips 
and incubated for 24 hr in 800 µL complete media. 
After 24 hr the cells were transfected with Fugene 6 
(#E2691, Promega) in accordance with the 
manufacturer’s directions. Fugene 6 transfection 
mixture was prepared by mixing 3 μL of Fugene 6 
with 97 μL of serum free media (SFM) and incubating 
at room temperature for 5 min. The diluted Fugene 6 
was then added to 1 μg of plasmid DNA in 98 μL of 
SFM. The mixture was incubated at room temperature 
for 30 min then 200 μL of the FuGENE 6:DNA 
complex was added dropwise to cells. The media was 
changed for fresh complete media after 5 hr and cells 
were subject to analysis 24 hr after transfection. 
Ligand Binding and Uptake: EGF, Alexa- 
labeled-EGF and Alexa-labeled-Transferrin  
Transfected cells were pre-incubated in 1 mL 
SFM for 1 hr at 37°C, 5% CO2. The SFM was then 
replaced with 500 μL of SFM containing one of the 
following ligands diluted in SFM: 20 ng/mL EGF 
(#E9644, Sigma); 8 μg/mL transferrin Alexa-488 
(#T-13342, Molecular Probes); 0.5 μg/mL Alexa-555 
EGF (#E35350, Molecular Probes); 0.5 μg/mL 
Alexa-488 EGF (#E13345, Molecular Probes). The cells 
were incubated in these ligand solutions for time 
periods up to 60 min. The culture plates were then 
placed on ice and rinsed 2x with ice-cold PBS prior to 
further analysis.  
Antibodies 
Western Blotting 
Mouse anti-HA HA.11 clone 16B12 (#MMS-101P, 
Covance, 1:1000). Goat anti-BCA2 (#SAB2500854, 
Sigma Aldrich, 1:500). Rabbit anti-EGFR 
(#HPA018530, Sigma, 1:1000). Mouse anti-Transferrin 
Receptor (#13-6800, Life Technologies, 1:500). Mouse 
anti-c-Met (#3127, Cell Signalling, 1:500). Rabbit 
anti-pEGFR Tyr1068 (#3777, Cell Signalling, 1,000). 
Rabbit anti-AKT (#9272, Cell Signalling, 1:1,000). 
Rabbit anti-pAKT Ser473 (#9271, Cell Signalling, 
1:500). Rabbit anti-ERK 1/2 (#9102, Cell Signalling, 
1:500). Rabbit anti-pERK 1/2 Thr202/Tyr204 (#9101, 
Cell Signalling, 1:500). Mouse HRP conjugated 
anti-β-tubulin (#ab21058, Abcam, 1:50,000). All 
secondary antibodies for Western blotting were from 
Pierce and were used at a dilution of 1:2000. 
Immunofluorescence microscopy (IF) 
Mouse anti-HA HA.11 clone 16B12 (#MMS-101P, 
Covance, 1:1000). Rabbit anti-EGFR  
(#HPA018530, Sigma, 1:100). Mouse anti-EEA1 
(#SC-6415, Santa-Cruz, 1:200).  Rabbit anti-LAMP2 
(#H4B4, DSHB, 1:200).  Rabbit anti-Rab7 (#9367, Cell 
Signalling, 1:100). Rabbit anti-HA (#3724, Cell 
Signalling, 1:1600). Rabbit anti-cathepsin D (#ab72915, 
Abcam, 1:100). Mouse anti-transferrin receptor 
(#13-6800, Life Technologies, 1:300). All secondary 
antibodies for IF were from Life Technologies and 
were used at a dilution of 1:400. 
Fluorescence microscopy  
Immunofluorescence 
PFA fixation for antibodies against: HA, EEA1, TfR and 
EGFR 
Cells cultured on glass coverslips were fixed in 
3% paraformaldehyde (PFA) for 15 min, free aldehyde 
groups were blocked with 50 mM NH4Cl for 10 min 
and cells were permeabilised for 5 min with 0.2% 
Triton X-100.  
Methanol fixation for antibodies against: HA, cathepsin D 
and LAMP2 
Cells cultured on glass coverslips were fixed in 
-20 °C, 100% methanol at -20 °C for 5 min then washed 
thrice in PBS. 
Single antibody immunolabeling for HA 
Following fixation, a solution of 2% FBS, 2% 
bovine serum albumin (BSA) in PBS was used to block 
non-specific binding sites via a 1 hr incubation. Cells 
were then incubated for 1 hr with anti-HA antibody 
diluted in blocking solution before being washed and 
incubated with Alexa labeled secondary antibody and 
Hoechst 33342 (#H3570, Life Technologies) at 1 
µg/mL for 1 hr. Washed coverslips were mounted 
onto glass slides and were imaged by confocal 
microscopy.  
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Double antibody immunolabeling for HA and either EGFR, 
EEA1, cathepsin D, TfR or LAMP2 
The protocol for double immunolabeling 
followed the protocol for single labeling until after the 
secondary antibody incubation. At this point the cells 
were blocked for a second time in 150 μL blocking 
buffer for 30 min before being incubated with the 
second diluted primary antibody (raised in a different 
species from either of the previously applied 
antibodies). After incubation for 1 hr at room 
temperature the coverslips were washed, then 
incubated with the appropriate species of Alexa 
labeled secondary antibody for 1 hr. Washed 
coverslips were then mounted onto glass slides for 
imaging. 
Double antibody immunolabeling for HA and Rab7 
The cells were fixed then incubated with NH4Cl 
as for single labeling. They were then blocked in 
150 μL of 5% BSA, 0.3% (v/v) Triton X-100 for 1 hr 
and subsequently incubated overnight with anti-Rab7 
antibody (4°C with gentle agitation in a humidified 
chamber). The antibody diluent was 1 % BSA, 0.3 % 
(v/v) Triton X-100. On the second day cells were 
incubated with Alexa labeled secondary antibody and 
Hoechst 33342 for 1 hr. The protocol for single 
antibody labeling for HA was then followed, though 
Hoechst was omitted from the final secondary 
antibody incubation. 
Microscopy  
Confocal fluorescence microscopy analysis was 
conducted on a Leica SP5 inverted confocal laser 
scanning microscope. The microscope was equipped 
with a 63x oil-immersion objective and 405, 488, 453 
and 633 nm excitation lasers. Gain and offset settings 
were optimized for each fluorescent channel within 
an experiment. Images were recorded using the 
sequential scanning mode to prevent fluorescence 
channel crosstalk/ bleed-through. Images were 
scanned at 100 Hz with a line average of three to 
reduce noise. 
Western blotting  
Cells were seeded in 6-well plates and grown in 
complete media to 70-80 % confluence on the day of 
lysate collection. Cell lysates were collected on ice by 
washing x1 in ice-cold PBS then scraping in 100 μL of 
lysis buffer (150 mM NaCl, 50 mM Tris base pH 8, 1 % 
NP-40 containing protease and phosphatase 
inhibitors). The lysates were centrifuged at 13,800 xg 
for 10 min at 4 °C and protein concentration of the 
supernatants was determined by bicinchoninic acid 
assay (BCA) assay. Samples were then mixed with 4x 
SDS-PAGE loading buffer before thermal 
denaturation at 96 °C for 5 min, and centrifugation at 
4°C, 13,800 g for 30 s. Proteins (18 μg total) were then 
separated by SDS-PAGE on a 10% acrylamide gel and 
were transferred to Polyvinylidene fluoride (PVDF) 
membrane. Membranes were blocked for 1 hr at room 
temperature in 5% milk in PBST (0.025% Tween20) 
and were incubated overnight at 4 °C with primary 
antibodies diluted in milk in PBST at the following 
dilutions: 5 % milk (anti-Tubulin), 3 % milk 
(anti-BCA2) or 2 % milk (all other primary 
antibodies). Membranes were washed in PBST before 
being incubated for 1 hr at room temperature with 
species specific secondary antibodies (diluted in 2 % 
milk in PBST). Before development, the membranes 
were washed again in PBST. Protein bands were 
detected by enhanced chemiluminescence (ECL). 
Band intensities were quantified using ImageJ 
software and normalized to loading control bands for 
housekeeping proteins.  
Antibody stripping for membrane reprobing 
After the first immunoblotting procedure had 
been completed and imaged, some membranes 
needed to be stripped and reprobed, to this end 
membranes were washed 2x 5 min in PBS then 2 x 5 
min in dH2O. The membranes were then stripped in 
0.2 M NaOH for 10 min before being washed twice 
more for 5 min in dH20 and 2 x 5 min in PBS. The 
membrane was then ready for the blocking step of the 
second immunoblotting procedure. 
Cell viability 
Cell viabilities were determined using the 
CellTiter-Blue® assay (#G8080, Promega) in 
accordance with manufacturer’s instructions. HeLa 
cells (3,500) were seeded into black 96-well plates and 
incubated overnight at 37°C, 5% CO2. The following 
day they were transfected with 0.1 μg HA-BCA2 or 
empty vector control and incubated under normal 
tissue culture conditions for 24 hr. Cells were then 
serum starved in SFM for 1 hr before being incubated 
for 48 hr with 100 µL of either: complete media, 
reduced-serum (0.5% FBS) media or reduced-serum 
media containing 20 ng/ml EGF. After 44 hr 
incubation, 20 μL of CellTiter-Blue reagent was added 
to each of the wells and the plates were returned to 
the incubator for 4 hr. The final fluorescence 
(544Ex/590Em) was measured using a Fluostar 
Optima fluorescent plate reader. 
Statistical methods 
Results are presented from either all the data 
from three independent experiments or representative 
images/immunoblots are shown (as indicated in the 
figures). Where replicates were performed (and data 
was quantitative) separate means were calculated for 
each independent experiment. Independent means 
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were then averaged to give an estimate of the true 
mean (µ) and 95% confidence intervals. Quantitative 
data are presented as means ± 95% confidence 
intervals (28). Prior to conducting statistical analyses 
to compare means, F-tests for heteroscedasticity were 
performed to determine whether a T-test for equal or 
unequal variance should be used. Student’s 
independent T-tests were performed when 
determining the significance of differences between 
two groups/means.  
GOBO: gene expression-based outcome  
The online biomarker assessment tool GOBO 
(http://co.bmc.lu.se/gobo)(29) was used to analyze 
the expression levels of BCA2 across different 
subgroups in a panel of 51 breast cancer cell lines 
based on Affymetrix ID 212742_at (BCA2) signal 
intensity. Mean log2 expression levels for each cell 
line were displayed by the software along with 
box-plots for each of the groups (Basal A, Basal B and 
luminal; Triple negative, HER2, and hormone 
receptor positive). Analysis of variance (ANOVA) 
statistics were automatically performed to assess 
differences between groups. 
Biomarker and survival analysis  
The KM Plotter online biomarker analysis tool 
(http://www.kmplot.com/) (30) was used to produce 
Kaplan-Meier plots for relapse free survival (RFS) and 
overall survival (OS) based on the signal intensity of 
Affymetrix ID 212742_at (BCA2). This probe set was 
chosen for the analysis as JetSet probes have been 
optimized for gene specificity, splice variant coverage 
and resistance to degradation (31). The dataset was 
divided into high and low expressing groups using 
the auto-select best cutoff. Survival curves were 
generated across all tumours and, in breast cancer, for 
analyses restricted according to ER status, HER2 
status and molecular subtype. The hazard ratio for 
RFS or OS with 95% confidence intervals and logrank 
P value were also calculated for low vs. high BCA2 
expression. 
Results 
BCA2 expression in a panel of cell lines  
BCA2 mRNA expression was analyzed in silico 
from a publicly available dataset of 51 breast (normal 
and cancer) cell lines using GOBO (29). Relative 
expression levels across the cell lines are presented in 
Figure 1A. Statistical comparison was also made 
between groups of cell lines divided according to 
basal or luminal type (Fig. 1B). A third analysis looked 
at BCA2 expression across cell line groups defined by 
HER2 positivity, hormone receptor positivity and 
triple negative subtypes (Fig. 1C). Mean BCA2 mRNA 
levels were higher in breast/breast cancer cell lines 
categorized as luminal (e.g. MCF-7 and T47D) though 
the difference in expression compared with basal A 
(e.g. MDA-MB-468) and basal B (e.g. MDA-MB-231) 
types was non-significant (Figure 1B, p=0.09616). The 
highest mean BCA2 expression was associated with 
hormone receptor positivity and lower mean BCA2 
expression levels were seen in the triple negative and 
HER2+ cell lines (Figure 1C). The difference in BCA2 
expression between triple-negative, HER2 and 
hormone receptor positive cell line classes was 
statistically significant (p=0.02912). 
We compared relative protein expression levels 
of BCA2 and EGFR in a selection of breast cell lines by 
Western blotting. Band intensities were quantified 
using ImageJ software, normalized to tubulin and 
expressed relative to MCF-10A levels (Fig. 1D). Our 
cell panel comprised immortalized breast epithelial 
cells (MCF-10A), luminal A, ER+ breast cancer cells 
(MCF-7 and T47D), triple-negative breast cancer 
(MDA-MB-231) and luminal B, HER2+ breast cancer 
(BT474). We also included the HeLa cervical 
carcinoma line in our analysis as EGFR trafficking in 
these cells is well characterized and they have been 
used in published studies of BCA2’s effects on 
receptor trafficking (15). Endogenous BCA2 
expression varied across these cell lines (Fig. 1D) and 
suggested a possible inverse relationship between 
BCA2 and EGFR expression. However, the panel of 
cell lines tested was not sufficiently large to perform 
meaningful correlation analyses. The immunoblots of 
BCA2 demonstrated two clear bands near the 
approximate predicted molecular weight of BCA2 (34 
kDa). Confirmation that these both represented BCA2 
was shown using siRNA depletion (supplementary 
Figure S1). In line with data in Figure 1D, BCA2 most 
often appears in the literature as a doublet (15, 17, 27, 
32). T47D and MCF-7 cells expressed the highest 
levels of BCA2 while HeLa expressed the lowest. 
MDA-MB-231 cells were also found to express 
relatively high levels, contrary to some published 
data, though in line with others and with the mRNA 
data in Figure 1A (18, 22).  
Heterogeneity of BCA2 localization and 
expression levels in transiently transfected 
MCF-7, MDA-MB-231 and HeLa cells  
The sub-cellular localization of endogenous 
BCA2, using different antibodies, has variously been 
described in the literature as: nuclear (MCF-7) (33); 
cytoplasmic and/or late endosome/ lysosome 
associated (BHK) (13); punctate cytoplasmic staining 
(MCF-7) (32); faint cytoplasmic and intense nucleolar 
staining (MCF-7) (21). In transfected 293T cells large 
cytoplasmic accumulations of BCA2 have been 
 Journal of Cancer 2016, Vol. 7 
 
http://www.jcancer.org 
2393 
demonstrated (27). The differences in reported 
subcellular localization may reflect true biological 
heterogeneity or may result from different 
experimental approaches. Given these discrepancies 
and the lack of validated commercially available 
antibodies, we decided to use transient expression of 
epitope tagged protein as an alternative means of 
characterising BCA2 localization. 
The HA-BCA2 plasmid was transfected into 
MCF-7, MDA-MB-231 and HeLa cells which, 24 hrs 
later, were fixed and immunolabeled for HA. 
HA-BCA2 transfected MCF-7 and HeLa cells both 
displayed a number of different, seemingly 
expression level-dependent phenotypes (Fig. 2, top 
and bottom rows). High BCA2 expressing cells either 
tended to display ubiquitous small, uniform vesicles 
throughout the cytoplasm or they contained large, 
dense perinuclear vesicles and/or large cytoplasmic 
structures. Cells expressing moderate BCA2 levels 
cells tended to have diffuse cytoplasmic staining with 
few sparsely distributed vesicles, whilst low 
HA-BCA2 expressing cells only showed a faint, 
diffuse cytoplasmic labeling. There was some 
evidence of nuclear labeling in the transfected cells 
but this was rare (<5% of transfected cells) and there 
was no evidence of BCA2 in nucleoli.  
 
 
Figure 1: Comparative BCA2 expression analysis. A-C) From GOBO dataset of 51 normal and malignant breast cell lines. A) Log2 BCA2 expression levels across all the cell lines. Green 
arrows indicate the cell lines chosen for Western blotting analysis in 1D.  B) Mean Log2 BCA2 expression compared between basal A, B and luminal A subtypes. C) Mean Log2 BCA2 
expression compared between triple negative, HER2 positive and hormone receptor positive disease. In A and B: Red = Basal A, Grey = Basal B and Blue = Luminal. D) Immunoblots of 
endogenous BCA2 and EGFR levels in a panel of cell lines. BCA2 protein levels quantified with ImageJ software, normalized to the tubulin loading control and their expression levels were 
calculated relative to MCF-10A cells. 
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Figure 2: Sub-cellular localization of HA-BCA2 in MCF-7, MDA-MB-231 and HeLa cells. Cells were transfected with HA-BCA2 and after 24 hr were fixed and immunolabeled for 
HA. Nuclei were counterstained blue with Hoechst. Blue arrowheads indicate vacuoles. Scale bars = 25 μm. 
 
HA-BCA2 over-expressing MDA-MB-231 cells 
(Fig. 2, middle row) showed signs of poor viability: 
most of the transfected cells appeared to be rounded 
or demonstrated cytoplasmic vacuolation. Owing to 
the poor viability no further experiments were 
performed on the MDA-MB-231 cells. 
In order to verify that the sub-cellular 
localisation in Figure 2 related to HA-tagged BCA2, 
i.e. to confirm that the protein was expressed and the 
HA-tag was uncleaved, double-immunolabeling was 
performed for BCA2 and HA. Co-localization analysis 
confirmed that immunofluorescence staining was 
specific to BCA2 and that the HA tag remained 
attached in vitro (Supplementary Figure S2A). Single 
labeling was also performed for both BCA2 and HA 
(Supplementary Figure S2B). The staining patterns 
seen in single-labeled cells were very similar, further 
indicating the structures/localisation seen were not 
artefacts of the double-labeling process. These 
experiments also validated the goat anti-BCA2 
antibody for use in immunofluorescence.   
BCA2 over-expression decreases EGFR levels 
in HeLa cells  
BCA2 has been shown to alter EGFR trafficking 
(13-15) but its effects on basal levels of this RTK have 
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not been directly explored. HeLa cells naturally 
express low levels of BCA2 (Fig. 1) and EGFR 
trafficking in these cells has been extensively studied. 
BCA2 depletion in HeLa cells has previously been 
shown to impair ligand induced degradation of both 
EGFR and c-Met (15). The HeLa cell line was therefore 
a useful model for studying the effects of BCA2 
over-expression on EGFR in cancer cells. We 
investigated BCA2 induced changes in total levels of 
the RTKs EGFR and c-Met and also of the 
(non-tyrosine kinase) transferrin receptor (TfR). 
Receptor levels were examined by Western blotting of 
cells transfected with HA-tagged BCA2 or the mock 
plasmid. Three independent, duplicate experiments 
showed a significant decrease in total EGFR (p=0.001) 
and c-Met (p=0.003) in the HA-BCA2 over-expressing 
cells (Fig. 3A-C); TfR expression was not significantly 
altered (p=0.365. Figures 3A and D).  
 
Figure 3: Relative levels of EGFR, c-Met and TfR in mock transfected control and HA-BCA2 over-expressing HeLa cells. A) Immunoblots for selected receptors in cells 
transfected with HA-BCA2 or mock transfected with an empty control vector. B-D) Protein expression was quantified with ImageJ software. Results from three independent, experiments 
carried out in duplicate are shown. Error bars represent 95% confidence intervals. ** p≤0.01. *** p≤0.001. E and F) Confocal microscopy images of EGFR in HA-BCA2 over-expressing HeLa 
cells. HA-BCA2 transfected cells were serum starved for 60 min then either E) stimulated with 20 ng/mL EGF for 15 min or F) incubated with EGF Alexa 488 for 30 min on ice. Cells were then 
fixed and immunolabeled for HA-BCA2 (red) and (in E only) for EGFR (green). Nuclei were stained blue with Hoechst. Representative images from two independent, duplicate experiments are 
shown. Scale bars = 50 µm. Arrowheads indicate examples of HA-BCA2 transfected cells. 
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In order to visualize the reduction in EGFR levels 
induced by BCA2 over-expression, two different 
experiments were performed. Firstly, cells were 
treated with EGF to induce EGFR accumulation in 
early endosomes and secondly cells were incubated 
with fluorescently labeled EGF on ice (9). Incubating 
cells with EGF at 4°C for 30 min allows the ligand to 
bind to surface receptors without inducing 
internalization (34).  
Figure 3E shows the results of double-labeling IF 
for HA and for EGFR following EGFR stimulation. 
HA-BCA2 transfected cells showed reduced 
accumulation of EGFR in intracellular vesicles. Figure 
3F demonstrates a trend of reduced EGF-488 binding 
to the HA-BCA2 over-expressing cells, indicative of 
reduced receptor numbers on the cell surface.  
Total expression levels of EGFR were also 
examined in MCF-7 cells following siRNA depletion 
of BCA2 in three independent Western blotting 
experiments (Supplementary Fig. S1). An 80% 
reduction in BCA2 was associated with a 2.5 fold 
increase in EGFR levels in the BCA2high/EGFRlow cell 
line (p=0.040) while levels of TfR were unaffected 
(p=0.451). This confirms in two different cell types 
that BCA2 expression can influence EGFR protein 
expression levels. 
BCA2 over-expression delays EGFR 
degradation in HeLa cells  
The binding of EGF to EGFR stimulates 
internalization and trafficking of the receptor-ligand 
complex, primarily to the lysosomes for degradation 
(34). BCA2 has been reported to alter ligand-induced 
degradation of EGFR, though there is some debate as 
to whether the protein promotes or inhibits 
degradation of the receptor (13-15). Having shown 
that total EGFR levels are influenced by changes in 
BCA2 expression we investigated the effect of BCA2 
over-expression on EGFR endocytic downregulation 
following EGF stimulation (Fig. 4).  
For Western blot analysis, HA-BCA2 and mock 
transfected HeLa cells were serum starved for 60 min 
then stimulated with 20 ng/mL EGF (or diluent 
control) for the same time period. Cell lysates were 
collected from three independent experiments 
conducted in triplicate. Following SDS-PAGE and 
transfer to PVDF, immunoblotting was performed for 
EGFR, HA and tubulin (Fig. 4A) and band-densities 
were quantified using ImageJ (Fig. 4B). Basal EGFR 
expression levels (t=0) were significantly reduced in 
HA-BCA2 over-expressing cells relative to mock 
transfected controls (p=0.002). Conversely, after 60 
min, significantly more EGFR persisted in the 
HA-BCA2 over-expressing cells (p=0.030) indicating 
that EGFR degradation was delayed as a result of the 
increase in BCA2 levels. 
We next monitored the endocytic degradation of 
EGFR by confocal microscopy of HA-BCA2 
over-expressing HeLa cells acutely stimulated with 
fluorescently labeled EGF. To control for potential 
general effects on endocytosis, we also used 
fluorescently labeled transferrin (Tf) in parallel 
experiments. Transfected cells were incubated for 15 
or 60 min with either 0.5 µg/mL Alexa-488 EGF or 8 
μg/mL Alexa-488 Tf. After incubation with the 
fluorescent ligands the cells were fixed and 
immunolabeled for HA-BCA2 (Fig. 4C and D).  
Figure 4C demonstrates that EGF internalization 
was initially reduced in the BCA2 over-expressing 
HeLa cells, as indicated by the low EGF-488 signal at 
15 min. After 60 min of incubation, EGF appeared to 
accumulate and persist in BCA2 over-expressing 
HeLa cells. In contrast, the majority of the EGF signal 
was lost in the non-transfected cells due to lysosomal 
delivery and degradation. This mirrors the results 
seen by Western blotting (Fig. 4A). There was little 
discernible difference in Tf uptake and distribution 
between HA-BCA2 over-expressing cells and 
non-transfected controls at either time point (Fig. 4D). 
Endocytic profile of BCA2 over-expressing 
HeLa with and without EGF  stimulation 
Having established that EGF degradation was 
delayed/impaired by HA-BCA2 over-expression, we 
sought to determine which endocytic compartments 
the EGF was retained in at the 60 min time point.  We 
also wanted to ascertain whether the endocytic profile 
of the transfected cells and/or the localization of 
BCA2 was altered in the EGF stimulated (and 
unstimulated cells). Following 60 min of serum 
starvation, HA-BCA2 over-expressing HeLa cells 
were either incubated with EGF-555 or diluent control 
for 60 min. After fixation, 
double-immunofluorescence labeling was performed 
for HA and either EEA1 (early endosomes), TfR 
(recycling endosomes), LAMP2 (late endolysosomes) 
or cathepsin D (lysosomes). Figure 5A-D shows that 
in both unstimulated (0 min EGF) and EGF stimulated 
(60 min EGF) cells there were no significant 
alterations in the sub-cellular localization or 
abundance of any of the immunolabelled 
endolysosomal compartments. HA-BCA2 localization 
remained heterogeneous in EGF stimulated and 
unstimulated cells: vesicles and cytoplasmic 
accumulations in a range of sizes and/or diffuse 
cytosolic labeling patterns were seen, as in Figure 2. 
After 60 min incubation, the signal from EGF-555 had 
largely been lost from untransfected cells, indicating 
degradation. In HA-BCA2 over-expressing cells 
however, EGF-555 accumulation was detected in early 
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(EEA1 positive) and late (LAMP2 positive) endosomal 
compartments (Fig. 5A and C red-blue channel merge 
[RB] insets). Little co-localisation was seen between 
EGF-555 and the cathepsin D positive and TfR 
containing compartments (Fig. 5B and D, RB-inset).  
 
 
Figure 4: EGFR and EGF degradation in HA-BCA2 over-expressing HeLa cells. A) HA-BCA2 and mock transfected HeLa cells were serum starved for 60 min then stimulated with 
20 ng/ml EGF for 0 or 60 min. Cell lysates were collected from three independent, triplicate experiments. Western blotting was performed for EGFR and HA. Representative blot of a single 
experiment is shown. B) Band intensities were quantified using ImageJ software. Error bars represent 95% confidence intervals. * p≤0.05. ** p≤0.01. C and D) Confocal microscopy images of 
endocytosed fluorescent EGF and Transferrin (Tf) in HA-BCA2 over-expressing HeLa cells. HA-BCA2 transfected cells were incubated with 0.5 µg/mL Alexa-488 EGF or 8 µg/mL Alexa-488 
Tf (both green) for 15 OR 60 min before being fixed and immunolabeled for HA (red). Nuclei were stained blue with Hoechst. Scale bar = 50 µm. Arrowheads indicate examples of HA-BCA2 
transfected cells. 
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Figure 5: Endocytic profile of HA-BCA2 
over-expressing HeLa cells ± EGF. HA-BCA2 
transfected cells were incubated with 0.5 µg/mL Alexa-555 
EGF (red) for 0 or 60 min before being fixed. A) Sequential 
immunolabeling of HA-BCA2 and EEA1 (early endosomes, 
blue). B) Co-incubation of Alexa-555 EGF and Tf-647 
(recycling endosomes, blue) and immunolabeling for 
HA-BCA2.  C) Sequential immunolabeling of HA-BCA2 and 
LAMP2 (late endosomes/lysosomes, blue). D) Sequential 
immunolabeling of HA-BCA2 and cathepsin D (lysosomes, 
blue). Scale bar = 50 µm. White arrowheads indicate examples 
of HA-BCA2 transfected cells. Inset is merge of red and blue 
channels to show co-localisation (purple) between endocytic 
markers and EGF. Green arrowheads indicate examples of 
co-localisation. 
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BCA2 over-expression alters downstream 
EGFR signalling in HeLa cells  
Upon EGF binding and receptor dimerization, 
the intracellular domain of EGFR becomes 
phosphorylated. This initiates downstream activation 
of oncogenic signalling, predominantly via the MAPK 
and PI3K/Akt pathways. EGFR is internalized 
following activation and there is a strong body of 
evidence to indicate that it continues to signal from 
endosomes and that receptor internalization is 
required for some components of downstream 
signalling (35, 36). We therefore hypothesised that the 
BCA2 induced changes in EGFR trafficking and 
degradation might alter downstream signalling 
pathways. Three independent experiments were 
performed to test this hypothesis. HA-BCA2 or mock 
transfected HeLa cells were serum starved then 
stimulated with 20 ng/mL of EGF for 5 or 60 min 
before lysates were collected on ice. No baseline 
phosphorylation of EGFR was observed in 
unstimulated cells (data not shown) so a 5 min pulse 
of EGF was selected as the earliest time point. Cell 
lysates were probed for HA and a panel of signalling 
proteins: total EGFR and phosphorylated EGFR 
(pEGFR, Tyr1068), total AKT and phosphorylated Akt 
(pAKT, Ser473) and total ERK1/2 and 
phosphorylated ERK (pERK, Thr202/Tyr204). The 
complete panel of immunoblots shown in Figure 5A 
was achieved by stripping and re-probing of PVDF 
membranes cut into low and high molecular weight 
strips. Band intensities were quantified using ImageJ 
software and protein activation was determined by 
the ratio of phosphoprotein to total protein (Fig. 6B 
and C). Activation of EGFR was examined by 
normalizing pEGFR to total EGFR and to Akt. Total 
Akt also acted as a loading control for pEGFR and 
thus enabled further information to be obtained about 
the relative proportion of active EGFR while taking 
into account changes in total EGFR levels.  
Quantification and student’s independent 
two-tailed t-test of the immunoblotting data in Figure 
6A revealed that after 5 min EGF stimulation there 
was a significant reduction in pEGFR, pAkt and pERK 
in BCA2 over-expressing HeLa cells compared with 
mock transfected controls (Fig. 6B). Conversely, after 
60 min EGF stimulation, significantly more EGFR, Akt 
and ERK remained active in the BCA2 
over-expressing cells compared with controls (Fig. 
6C). Examining the ratios of pEGFR/total EGFR and 
pEGFR/total AKT we found that at 5 min the 
reduction in EGFR activation in HA-BCA2 
over-expressing cells was proportional to the 
reduction in total receptor level. However, after 60 
min of EGF stimulation, a greater proportion of the 
remaining EGFR was active in the HA-BCA2 
over-expressing cells. Overall this suggests that BCA2 
over-expression can influence the endocytic signalling 
and degradation of EGFR. 
BCA2 over-expression reduces HeLa cell 
viability  
The above results indicated that BCA2 
over-expression elicited a downstream EGFR 
signalling response of reduced magnitude (at 5 min) 
but prolonged duration (at 60 min). We wondered 
whether these changes in signalling translated to 
changes in cell growth. HA-BCA2 or mock transfected 
HeLa cells were serum starved for 1 hr, prior to a 
further 48 h incubation in either reduced serum media 
(0.5% FBS), in media supplemented with 10% FBS or 
in reduced serum media supplemented with 20 
ng/ml EGF. Cell viability was assessed using a 
Cell-titre blue assay. Data from three independent 
experiments conducted in triplicate were processed 
by converting mean fluorescence intensity values to 
“cell viability” as a percentage of mock-transfected 
controls grown in complete media (10% serum). The 
viability of HA-BCA2 over-expressing cells was 
modestly but statistically significantly lower than 
control cells in all tested conditions (Figure 7).  
The relationship between BCA2 and Rab7 in 
HeLa cells.  
BCA2 and Rab7 have previously been shown to 
interact (13). We therefore decided to examine the 
sub-cellular localization of Rab7 in cells transiently 
transfected with HA-BCA2. These cells were 
sequentially labeled for Rab7 and HA and were then 
imaged by confocal microscopy. The untransfected 
cells featured perinuclear clusters of Rab7 positive 
vesicles whereas in HA-BCA2 over-expressing cells 
we observed an overall reduction in Rab7 
fluorescence and in the number of the Rab7 positive 
vesicles (Fig. 8A). Contrary to previous reports in the 
literature (13) we did not find evidence of 
co-localization between the over-expressed BCA2 and 
Rab7 proteins.  
Others have previously reported co-localization 
between enhanced green fluorescence protein (EGFP) 
tagged Rab7 and BCA2 (13). We therefore examined 
the sub-cellular localization of HA-BCA2 and 
EGFP-Rab7 in transiently co-transfected cells. 
EGFP-Rab5, a marker of early endosomes with no 
reported links to BCA2, was studied in parallel. 
Whilst we observed some co-localization of BCA2 
with EGFP-Rab7 in the perinuclear area, we also 
found that HA-BCA2 co-localized with EGFP-Rab5 on 
peripheral vesicles (Supplementary Figure S3). Since 
we were unable to demonstrate the specificity of 
BCA2 and Rab7 co-localization with a dual 
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over-expression approach, no further experiments 
were performed using the EGFP-Rab constructs. 
Rab proteins are delivered by chaperone 
proteins to membranes and interact with lipids via 
geranylgeranyl tails located at their C-terminus. (37). 
The reduction in vesicular Rab7 labeling seen in 
Figure 8A could have reflected a redistribution of 
Rab7 to the cytosol or alternatively a decrease in total 
Rab7 protein levels in the transfected cells. To 
distinguish between these two possibilities, Rab7 
protein levels were examined in HA-BCA2 
over-expressing and mock transfected HeLa cells after 
5 and 60 min EGF incubation, as described 
in Figure 6. The data in Figure 8B 
demonstrate that Rab7 levels were 
unchanged by HA-BCA2 over-expression 
at either time point with EGF. This suggests 
that the loss of vesicular Rab7 seen by IF 
was the result of altered localization rather 
than a reduction in protein level.  
 
 
Figure 6:  EGFR activation and signalling in HA-BCA2 
over-expressing HeLa cells following. HA-BCA2 and mock 
transfected cells were serum starved for 60 min then stimulated with 20 
ng/mL EGF for 5 or 60 min. Cell lysates were collected from three 
independent experiments. A) Western blotting was performed for EGFR, 
pEGFR (Tyr1068), AKT (Ser473), pAKT, ERK, pERK (Thr202/Tyr204) and 
HA. Band intensities were quantified using ImageJ software and are 
presented as the amount of pEGFR normalized to total EGFR, amount of 
pEGFR normalized to total AKT, amount of pAKT normalized to total 
AKT and amount of pERK normalized to total ERK. B) Relative amount of 
phosphorylated proteins at 5 min. C) Relative amount of phosphorylated 
proteins at 60 min. Error bars represent 95% confidence intervals. ** p ≤ 0.01. 
*** p ≤ 0.001. 
  
 Journal of Cancer 2016, Vol. 7 
 
http://www.jcancer.org 
2401 
 
Figure 7: The effect of BCA2 over-expression on the viability of transiently transfected HeLa cells. HA-BCA2 or Mock transfected cells were either serum-starved (0.5% FBS) 
or grown for 48 hr in the presence of 10% FBS or 20 ng/ml EGF in 0.5% serum-containing media. Cell viability was analyzed by CellTitre- Blue™ assay. Results from three independent, triplicate 
experiments were normalized to mock transfected control cells grown in FBS. Error bars represent 95% confidence intervals. ** p≤0.001. 
 
Figure 8: Rab7 sub-cellular localization and expression levels in HA-BCA2 over-expressing HeLa cells. A) Confocal microscopy of HA-BCA2 (red) over-expressing cells 
following sequential immunlabeling for Rab7 (green) then HA (Red). Nuclei were stained with Hoechst (blue). Arrowheads indicate examples of HA-BCA2 transfected cells. Scale bars = 50 μm. B) 
Immunoblot showing Rab7 levels in mock transfected and HA-BCA2 over-expressing HeLa following EGF stimulation. HA-BCA2 and mock transfected cells were serum starved for 60 min 
then stimulated with 20 ng/mL EGF for 5 or 60 min. Cell lysates were prepared from three independent experiments (repurposed from experiment in Figure 6) and probed for HA and Rab7. 
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Biomarker and survival analysis 
KM Plotter (http://www.kmplot.com/) is an 
online analysis tool that integrates microarray 
expression data with clinical information from a large 
cohort of 10,188 patient samples: 4,142 breast, 1,648 
ovarian, 2,437 lung and 1,065 gastric cancer patients. 
Users can examine the impact on survival of different 
levels of gene expression for over 50,000 target genes 
(30). For this study the data were split into high and 
low expressing groups and survival curves were 
generated across all breast, ovarian, lung and gastric 
cancers. Survival was also examined in breast cancer 
analyses restricted according to estrogen receptor 
(ER) status, molecular subtype and HER2 expression. 
The hazard ratio for survival with 95% confidence 
intervals and logrank P value were automatically 
calculated for low vs. high expression.  
Survival curves generated with KM Plotter for 
high versus low BCA2 expression in breast cancer 
show that BCA2 significantly impacts on RFS in this 
disease and that survival effects are subtype 
dependant (Fig. 9).  
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Figure 9: Kaplan-Meier survival curves for high vs. low BCA2 mRNA expression in breast cancer created using KM Plotter (30). Probability of relapse free survival in high 
(red) or low (black) BCA2 expressing breast cancer is compared. A) Survival across all tumours. B) Survival in ER+ vs. ER- disease. C) Survival in HER2+ vs. HER2- disease. D) Survival stratified 
according to molecular subtype. 
 
Plots for low versus high BCA2 expression show 
that breast cancers expressing high levels of BCA2 
were associated with poorer prognosis: the hazard 
ratio (HR) for RFS across all tumours was 1.18, 
P=0.0046. Significantly reduced RFS was 
demonstrated in high BCA2 expressing breast cancers 
that were HER2 positive (HR=2.62, p=0.0021). In the 
HER2 over-expressing molecular subtypes luminal B 
and HER2, high BCA2 expression was also associated 
with reduced survival (Luminal B: HR=1.41, p=0.0018 
and HER2: HR=1.54, p=0.044). Conversely, high levels 
of BCA2 in ER+ and HER2- disease were associated 
with improved patient prognosis (ER+: HR=0.73, 
p=0.0011 and HER-: HR=0.67, p=0.0055). 
The effect of BCA2 on overall survival (OS) in 
lung, gastric and ovarian cancers was examined using 
KM Plotter to determine whether BCA2 was also a 
potential biomarker in cancers other than those of the 
breast (Fig. 10). High BCA2 expression was associated 
with poorer survival in gastric (HR=1.43, p=0.000035) 
and ovarian cancer (HR=1.24, p=0.0051). Conversely, 
high BCA2 expression appeared to be associated with 
increased overall survival in lung cancer, however, 
this narrowly missed reaching statistical significance 
(HR=0.86, p=0.051). 
Discussion  
Our results here demonstrating that BCA2 
over-expression reduces total EGFR levels while 
inhibiting the receptor’s degradation initially appear 
to be contradictory. Others have shown that EGFR 
degradation is inhibited by the BCA2-Rab7 interaction 
(13) and supporting a relationship between the two 
proteins we found that HA-BCA2 over-expression 
appeared to induce a failure of Rab7 membrane 
association. siRNA depletion of Rab7 has been shown 
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to reduce the lysosomal degradation of EGFR while 
inducing a concomitant decrease in total levels of the 
receptor (7, 9). Thus the strongest hypothesis to 
explain our data is that over-expressed BCA2 
sequesters Rab7 in the cytosol, preventing the GTPase 
from carrying out its endosomal function on the 
membrane. In this manner BCA2 over-expression 
produces cellular effects analogous to Rab7 depletion. 
Sequestration of interacting proteins is a documented 
effect of transient over-expression systems (38, 39).  
The finding that BCA2 over-expression inhibits 
EGFR trafficking is directly supported by some 
literature (13) but appears to be contrary to others (14, 
15). Sakane and colleagues suggested that BCA2 
over-expression accelerates ligand induced EGFR 
degradation in cells transfected with BCA2 and EGFR 
(14). However, the HEK293 cell line used did not 
readily degrade EGFR in response to EGF stimulation: 
after three hours the receptor levels were only 
reduced to 80% in the mock-transfected control cells. 
A separate experiment was performed in which cells 
were transfected with BCA2 plus EGFR, ubiquitin and 
c-Cbl and here EGFR was extensively down-regulated 
in response to EGF stimulation. Under these 
conditions, EGFR degradation was inhibited in BCA2 
over-expressing cells compared with control, just as 
we have shown in Figure 4. Supporting our Rab7 
sequestration hypothesis were further data from this 
study showing that a BCA2 RING mutant produced a 
greater inhibitory effect on EGFR degradation than 
wild-type protein (14). The BCA2 RING mutant has 
been shown to lack E3-ligase (and autoubiquitination) 
activity (33) but, with an intact N-terminus, should 
still able to bind Rab7 (13). Enhanced inhibition of 
EGFR degradation by the RING mutant may therefore 
reflect intracellular accumulation of 
autoubiquination-deficient BCA2, leading to 
increased cytosolic sequestration of Rab7. 
 
 
 
Figure 10: Kaplan-Meier survival curves for high vs. low BCA2 mRNA expression in lung, gastric and ovarian cancer created using KM Plotter (30). Probability of overall 
survival in high (red) or low (black) BCA2 expressing is compared in A) lung cancer B) gastric cancer and C) ovarian cancer. 
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Another BCA2 study that invites comparison 
with our research, is that conducted by Smith et al. 
(15). As in our experiments, the relationship between 
BCA2 and EGFR trafficking was investigated in a 
HeLa cell model. An siRNA approach was used for 
the studies and BCA2 depletion was shown to delay 
EGFR degradation. EGFR activation was also 
examined and here the BCA2 siRNA increased EGFR 
phosphorylation and promoted association of EGFR 
with the signalling protein SHC1. We extend this 
work by showing novel downstream signalling effects 
in a BCA2 over-expression system. Our findings 
indicate that EGF stimulation of BCA2 
over-expressing cells gives rise to a reduced but more 
prolonged signalling response in MAPK (ERK1/2) 
and Akt pathways. The consequences of such a 
signalling pattern are not fully resolved, though they 
may be connected to the reduced cell viability seen in 
Figure 7. Our findings in Figure 6 are supported by 
the persistence of EGF in the (EEA1 positive) early 
endosomes of HA-BCA2 over-expressing cells since 
EGFR is known to signal from this endocytic 
compartment (40). 
BCA2 over-expression (Figs. 4-7) and depletion 
(15) in the same cell line have now been shown to 
similarly influence EGFR trafficking. We hypothesise 
that in our studies BCA2 over-expression produces a 
dominant negative phenotype, equivalent to that 
produced by protein depletion. This may be a result of 
disrupted stoichiometry between BCA2, Rab7 and/or 
other interactors, an effect reported in the literature 
for other over-expressed proteins (38, 39).  
Since caspase 3-mediated cleavage of EGFR has 
been shown to occur concomitantly with reduced 
receptor degradation during apoptosis (41), our data 
in Figures 3 to 7 could alternatively be explained by 
cytotoxicity induced by over-expression e.g. by 
aggregate/aggresome formation. Aggresomes are 
cytoplasmic inclusions containing deposits of 
ubiquinated, often misfolded, proteins and are 
believed form when the production rate of 
aggregation-prone proteins exceeds proteasome 
capacity (42). Despite heterogeneity, the most 
commonly seen patterns of HA-BCA2 localization 
were large perinuclear and cytoplasmic inclusions. 
Such localization has also been seen in the literature 
(13, 27, 43) and may indicate a natural tendency for 
the protein to cluster and/or aggregate, especially at 
high expression levels. The accumulation of protein 
aggregates is known to affect cell signalling and to 
induce cytotoxicity (44, 45); it is a recognized potential 
limitation of transient transfection (46). The use of an 
inducible gene expression system, where the levels of 
BCA2 protein could be tuned, would potentially be 
more informative for further investigations. 
In vitro data presented here and in the literature 
suggest that exogenous manipulation of BCA2 
expression may have context-dependent effects on 
cancer cell survival. We found that over-expression of 
BCA2 was well tolerated by MCF-7 cells but not by 
MDA-MB-231s. Interestingly, siRNA depletion of 
BCA2 has been shown to reduce cell growth in both 
the MCF-7 and MDA-MB-231 cell lines (17, 22), while 
pharmacological BCA2 inhibition results in differing 
cytotoxic effects: MCF-7 cells are sensitive to BCA2 
inhibitors but MDA-MB-231 are not (18). The effect of 
BCA2 over-expression on cell viability/proliferation 
has previously been examined in NIH3T3 mouse 
embryonic fibroblast cells and in these cells, 
proliferation was promoted by transfection with 
BCA2 (17). We, however, show a reduction in HeLa 
cell viability upon BCA2 over-expression. The 
difference between these viability findings could 
relate to inter-cell line variation in the expression of 
BCA2 partner proteins, RTKs and/or endocytic 
regulators. The cytotoxicity induced by BCA2 
over-expression in HeLa cells is further evidence to 
support our hypothesis that over-expressing BCA2 
produces a double negative phenotype that is akin to 
functional depletion of Rab7. siRNA depletion of 
Rab7 has been shown to promote cell death (9); 
sequestration of Rab7 by over-expressed BCA2 would 
therefore explain our findings. A network of the 
possible mechanisms linking BCA2 over-expression 
with cell viability and EGFR regulation is presented in 
Supplementary Figure S4. 
Whilst the cells in this study were engineered to 
artificially over-express BCA2, high expression levels 
of this protein have been observed in breast cancer 
patients. Further experiments in breast cancer cell 
models would need to be performed to determine 
whether/to what extent our findings in HeLa cells 
apply to breast cancer specifically.  
In this study we have provided new in silico 
evidence that high levels of BCA2 may be associated 
with reduced relapse-free survival across all breast 
cancers. One previous study linked high levels of 
BCA2 to increased disease-free survival for regional 
recurrence and reduced lymph node metastasis (17). 
In this study by Burger et al. the relationship between 
BCA2 and the positive prognostic indicators was not 
thought to be a functional consequence of BCA2 
expression. BCA2’s association with reduced 
recurrence and metastasis was attributed to the high 
incidence of BCA2 upregulation in ER+ breast cancer, 
the most readily treatable form of the disease. Our 
data however suggest that BCA2 may in fact have an 
independent functional impact on breast cancer 
prognosis rather than simply a bystander correlation 
with other positive prognostic indicators. This can be 
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inferred as a positive relationship between BCA2 
expression and survival is apparent in the ER+ group 
following stratification. Interestingly in the ER- cohort 
BCA2 appears to impinge on prognosis, although this 
effect did not reach statistical significance. 
The relationship between BCA2 expression and 
RFS in breast cancer has not been previously 
examined by subtype but was examined here. Our 
data indicated that high levels of BCA2 adversely 
affect survival in HER2 over-expressing cancers but 
was associated with better prognosis in HER2- 
disease. The relationship between BCA2 and HER2 is 
further evident as high BCA2 expression impinged on 
RFS in the HER2-type and luminal B type breast 
cancers, both of which express high levels of the HER2 
oncoprotein. BCA2’s apparent link with HER2 in 
breast cancer survival may actually relate to the role 
of BCA2 in EGFR regulation rather than reflecting a 
direct relationship with HER2.  EGFR over-expression 
is most commonly seen in basal-type breast cancer but 
elevated levels of the receptor are often concomitant 
with HER2 positivity (47). Nonetheless a connection 
between BCA2 and HER2 has not been previously 
made in the literature and therefore may be a 
productive avenue for further research.  
We extended our in silico studies to examining 
the relationship between BCA2 expression and overall 
patient survival in lung, gastric and ovarian cancer. 
We demonstrated a novel, anatomical-context 
dependent relationship between BCA2 expression 
and OS. High BCA2 expression was associated with 
poorer prognosis in gastric and ovarian cancers but 
was associated with better prognosis in lung cancer. 
Exploration of the mechanism/s connecting BCA2 
and survival in other cancers is beyond the scope of 
this study. However, our findings add to the body of 
evidence that the role of BCA2 in cancer is contingent 
on the biological context.  
Conclusions 
The accumulated data from our studies suggest 
that BCA2 has an important, context dependent role 
as a prognostic biomarker in cancer with both positive 
and negative contributions. Our findings indicate that 
the protein has a regulatory function in the trafficking 
and expression of EGFR, impacting on the signalling 
and viability of cancer cells. Developing a deeper 
understanding of BCA2’s context dependency will be 
essential for determining whether BCA2 is a potential 
therapeutic target in breast cancer. 
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merge inset; RFS: Relapse free survival; RPMI: 
Roswell Park Memorial Institute media; RTK: 
Receptor tyrosine kinase; SFM: Serum free media; Tf: 
Transferrin; TfR: Transferrin receptor. 
Supplementary Material  
Supplementary figures and method.  
http://www.jcancer.org/v07p2388s1.pdf 
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